News & Events CTI Announces Jim Westerkamp Promoted to Vice President, Consulting Operations

CTI Announces Jim Westerkamp Promoted to Vice President, Consulting Operations

July 17, 2017

CTI Clinical Trial & Consulting Services Announces Jim Westerkamp Promoted to Vice President, Consulting Operations

FOR IMMEDIATE RELEASE [Covington, KY ~ July 17, 2017]

CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces Jim Westerkamp has been promoted to Vice President, Consulting Operations.

Jim's leadership and dedication to CTI over the last decade have shaped the Consulting department into a robust group of global experts in all aspects of clinical development, said Lynn Fallon, President. Were looking forward to his continued contributions to the team as the company continues to evolve and grow." 

Westerkamp has been a critical team member at CTI, contributing to its growth and success since he joined the company in 2006. He is responsible for the management of the Consulting Department, which includes the Regulatory and Scientific Affairs team and the Health Economics and Outcomes Research team. Westerkamp has been instrumental over the last decade in leading the Consulting Department, mentoring research associates and junior staff members, participating in business development activities, and managing clients. He has more than 25 years of academic and industry experience, including time as a certified histocompatibility specialist and as a molecular laboratory manager at The Ohio State University Medical Center.  Prior to joining CTI, Westerkamp also served as a Medical Science Liaison at Astellas Pharma US, Inc. and he spent time in sales roles at Chemicon International and Pel-Freez Clinical Systems.

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTIs focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com

Join Our Mailing List